. Author manuscript; available in PMC: 2023 Jun 1.

Published in final edited form as: Hematol Oncol Clin North Am. 2022 May 11;36(3):539–551. doi: 10.1016/j.hoc.2022.03.003

Table 1.

Summary of important WW studies for patients with locally advanced rectal cancer treated with neoadjuvant therapy

Study	N	NAT Strategy	Regrowth, n (%)	Salvage Therapy, n (%)	Overall Survival, %
Habr-Gama et al,³⁷ 2004	71	LCRT	2 (3%)	2 (100%)	OS: 100%, DFS: 92%
Smith et al,⁶⁵ 2012	32	LCRT	6 (18.8%)	6 (100%)	OS: 96%, DFS: 88%
Habr-Gama et al,²³ 2014	90	LCRT	28 (31%)	26 (92.8%)	OS: 91%, DFS: 68%
Appelt et al⁶⁶, 2015	40	LCRT	9 (25.9%)	9 (100%)	OS: 100%
Lai et al⁶⁷, 2016	18	LCRT	2(11%)	2 (100%)	OS: 100%, DFS: 69.78
Martens et al⁶⁸, 2016	100	LRCT: 95% SCRT: 5%	15(15%)	15 (100%)	OS: 96.6%, DFS: 80.6%
OnCore Project⁶⁹, 2016	129	45 Gy w/5-FU	44(34%)	41 (93.2%)	OS: 96%, DFS:88%
IWWD Consortium,³⁶ 2019	880	LCRT: 91%	213 (25.3%)	148 (69.5%)	OS: 85%, DFS: 94%
Smith et al, 2019⁵⁹	113	LCRT: 31(27%) Induction: 47(42%) Consolidation: 33 (29%) Chemotherapy alone: 2(2%)	22 (19.5%)	22 (100%)	OS: 73%, DFS: 75%
Jimenez-Rodriguez et al,⁶⁰ 2021	33	Induction TNT (FOLFOX)	2 (6%)	2(100%)	OS:97%, DFS:94%
Garcia-Aguilar et al (OPRA Trial),⁵⁶ TBD	307 (Total study accrual)	TNT (Induction & Consolidation chemotherapy)	N/A	N/A	DFS: 78% (Induction) vs 77% (Consolidation)

Abbreviations: DFS, disease-free survival; IWWD, International Watch and Wait Database; LCRT, long-course radiotherapy; OS, overall survival; SCRT, short-course radiotherapy; TNT, total neoadjuvant therapy.